Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Biomarkers for Alzheimer’s Disease Drug Development -

Biomarkers for Alzheimer’s Disease Drug Development

Robert Perneczky (Herausgeber)

Buch | Hardcover
372 Seiten
2018 | 1st ed. 2018
Humana Press Inc. (Verlag)
978-1-4939-7703-1 (ISBN)
CHF 164,75 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

 

Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. 

Epidemiology of Dementia: The Burden on Society, the Challenges for Research.- Population-based Approaches to Alzheimer’s Disease Prevention.- Systems Biology Methods for Alzheimer’s Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials.- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform.- CSF N-glycomics using MALDI MS Techniques in Alzheimer’s Disease.- MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid.- Validation of a Chemiluminescence Immunoassay for Measuring  Amyloid-β in Human Blood Plasma.- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer’s Disease Research.- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases.- Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development.- Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies.- Hybrid PET-MRI in Alzheimer’s Disease Research.- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers.- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia.- Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography.- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.- Unbiased Lipidomics and Metabolomics of Human Brain Samples.- Neuropathological Assessment as an Endpoint in Clinical Trial Design.- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery.- Telomere length shortening in Alzheimer’s disease – procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study.- Quantifying miRNA Deregulation in Alzheimer’s Disease.- Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET.- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models.- Cognitive Assessment in Alzheimer’s Disease Clinical Trials.- Data Mining and Machine Learning Methods for Dementia Research. 

Erscheinungsdatum
Reihe/Serie Methods in Molecular Biology ; 1750
Zusatzinfo 45 Illustrations, color; 9 Illustrations, black and white; XV, 372 p. 54 illus., 45 illus. in color.
Verlagsort Totowa, NJ
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Geriatrie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Schlagworte Alzheimer's disease (AD) • Alzheimer’s disease (AD) • Biomarker development • blood-based biomarkers • Cerebrospinal Fluid • Disease-modifying drugs • drug discovery • Magnetic Resonance Imaging • neuroimaging • Neuropathology • Personalized medicine
ISBN-10 1-4939-7703-2 / 1493977032
ISBN-13 978-1-4939-7703-1 / 9781493977031
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Gisela Mötzing; Susanna Schwarz

Buch | Softcover (2022)
Urban & Fischer in Elsevier (Verlag)
CHF 46,15
Das Wichtigste für Ärztinnen und Ärzte aller Fachrichtungen

von Klaus Hager; Olaf Krause

Buch | Softcover (2021)
Urban & Fischer in Elsevier (Verlag)
CHF 51,80
Zukunftssicherheit der Geriatrie - Konzept und Bedarfszahlen

von Bundesverband Geriatrie e.V.

Buch | Softcover (2023)
Kohlhammer (Verlag)
CHF 49,95